Tag: KDC-MN-387

  • Estradiol (Research)

    Endogenous estrogen / ER-alpha and ER-beta agonist

    17-beta-estradiol; the principal endogenous estrogen and the foundational compound of estrogen pharmacology.

    Abstract

    Estradiol (17-beta-estradiol, E2; CAS 50-28-2; molecular formula C18H24O2; molecular weight 272.39) is the principal endogenous estrogen, biosynthesized from testosterone (and androstenedione) by aromatase in ovary, adipose tissue, brain, and bone. The compound is a high-affinity full agonist at estrogen receptors ER-alpha and ER-beta (Ki approximately 0.1 nM at both), with downstream genomic effects on estrogen-responsive gene transcription and rapid non-genomic effects through membrane-associated signaling. Approved indications include menopausal hormone therapy (multiple oral, transdermal, vaginal, and parenteral formulations), prevention of postmenopausal osteoporosis, hypoestrogenism (Turner syndrome), and as part of gender-affirming feminizing hormone therapy. Pharmacokinetics depend strongly on formulation: oral micronized estradiol undergoes substantial first-pass metabolism; transdermal forms (patches, gels, sprays) bypass first-pass and produce more physiological plasma levels. Schedule N (non-controlled). Used as the canonical estrogen receptor agonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.